Biogen Inc logo

Biogen Inc

$ 291.60 +0.7 (+0.24%) 11:08 PM EST
P/E:
14.85
P/B:
3.29
Market Cap:
$ 41.99B
Enterprise V:
$ 43.61B
Volume:
754.55K
Avg Vol (2M):
1.16M
Also Trade In:
Volume:
754.55K
Market Cap $:
41.99B
PE Ratio:
14.85
Avg Vol (2-Month):
1.16M
Enterprise Value $:
43.61B
PB Ratio:
3.29
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for Biogen Inc ( ) from 1991 to Feb 02 2023. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Biogen stock (BIIB) PE ratio as of Feb 02 2023 is 14.85. More Details

Biogen Inc (BIIB) PE Ratio (TTM) Chart

To

Biogen Inc (BIIB) PE Ratio (TTM) Historical Data

Total 1222
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Biogen PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2023-02-02 14.8 2022-11-28 14.9
2023-02-01 14.8 2022-11-25 15.5
2023-01-31 14.8 2022-11-23 15.4
2023-01-30 14.6 2022-11-22 15.6
2023-01-27 14.8 2022-11-21 15.4
2023-01-26 14.9 2022-11-18 15.4
2023-01-25 14.9 2022-11-17 15.4
2023-01-24 14.9 2022-11-16 15.3
2023-01-23 14.9 2022-11-15 15.3
2023-01-20 14.6 2022-11-14 15.2
2023-01-19 14.3 2022-11-11 14.7
2023-01-18 14.4 2022-11-10 14.8
2023-01-17 14.7 2022-11-09 14.4
2023-01-13 14.7 2022-11-08 14.6
2023-01-12 14.7 2022-11-07 14.5
2023-01-11 14.5 2022-11-04 14.3
2023-01-10 14.3 2022-11-03 14.3
2023-01-09 14.0 2022-11-02 14.2
2023-01-06 14.2 2022-11-01 14.3
2023-01-05 13.8 2022-10-31 14.4
2023-01-04 13.8 2022-10-28 14.5
2023-01-03 13.9 2022-10-27 14.2
2022-12-30 14.1 2022-10-26 14.3
2022-12-29 14.1 2022-10-25 13.9
2022-12-28 13.9 2022-10-24 14.0
2022-12-27 14.0 2022-10-21 13.6
2022-12-23 14.2 2022-10-20 13.4
2022-12-22 14.3 2022-10-19 13.5
2022-12-21 14.6 2022-10-18 13.8
2022-12-20 14.6 2022-10-17 13.7
2022-12-19 14.5 2022-10-14 13.5
2022-12-16 14.5 2022-10-13 13.7
2022-12-15 14.4 2022-10-12 12.9
2022-12-14 14.7 2022-10-11 12.9
2022-12-13 14.8 2022-10-10 13.0
2022-12-12 14.8 2022-10-07 13.1
2022-12-09 14.5 2022-10-06 13.3
2022-12-08 14.7 2022-10-05 13.3
2022-12-07 14.9 2022-10-04 13.6
2022-12-06 14.8 2022-10-03 13.5
2022-12-05 14.9 2022-09-30 13.6
2022-12-02 15.2 2022-09-29 13.5
2022-12-01 15.4 2022-09-28 14.1
2022-11-30 15.5 2022-09-27 14.1
2022-11-29 14.8 2022-09-26 14.0

Biogen Inc (BIIB) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.